Neurobiological Technologies About
Neurobiological Technologies Neurobiological Technologies, Inc.
(NTI) (Nasdaq: NTII) is a biotechnology company engaged in the business of acquiring
and developing central nervous system (CNS) related drug candidates. The company
is focused on therapies for neurological conditions that occur in connection with
dementia, Alzheimer's
disease,
ischemic stroke, neuropathic
pain, and brain
cancer. PIPELINE
FOR NEUROBIOLOGICAL TECHNOLOGIES Memantine (Namenda)
is being evaluated as a potential neuroprotectant or neuromodulatory drug
to treat progressive neurological impairment due to neuronal injury. XERECEPT®
is the company's synthetic preparation of the natural human peptide CRF.
In preclinical studies, XERECEPT has been demonstrated to be an inhibitor of
swelling, or edema. VIPRINEX™ (ancrod), derived from the venom
of the Malayan pit viper, is a thrombin-like enzyme that is highly specific to
fibrinogen, a protein involved in blood clotting. When administered systemically
to stroke patients, Viprinex™ has been shown to rapidly deplete plasma
fibrinogen, the effects of which include anticoagulation, improved blood
viscosity and a secondary fibrinolytic or clot lysing action. More
Info on Neurobiological Key
Statistics for Neurobiological
Basic Chart
for Neurobiological